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PE during incubation with control solutions (methyl acetate: BEL 
solvent; Krebs buffer or R-BEL; PE alone: 9.8 [2.5] mN; PE with 
controls: 7.1 [2.0] mN: P = 0.012, Wilcoxon). Incubation with S-BEL 
had not effect on contraction to KCl 60 mM compared with incu-
bation with controls (methyl acetate, Krebs buffer, or R-BEL]. The 
post–S-BEL washout contractile response to PE was abolished (PE 
post–S-BEL: -1.2 [0.7] mN; P = 0.002, Friedman test; P = 0.028 vs 
pre–S-BEL PE response). Contraction to PE after washout of con-
trols was similar to initial PE responses. Effects were similar for 
S-BEL 25 uM versus S-BEL 12.5 uM on contractile responses to PE. 
Propranolol (50 mM) prevented contraction to phenylephrine alone 
and the early effect of S-BEL to enhance contractile responses to PE.
Conclusion: S-BEL has complex, biphasic, time-dependent effects 
on PE-mediated arterial constriction. Propranolol is both a beta-
adrenergic antagonist and inhibitor of PAP-1. Although S-BEL selec-
tively inhibits iPLA2β , our findings suggest that other targets may 
also contribute to modulation of PE-dependent arterial contraction.
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Introduction: Hypertension (HBP) is a disease with high morbidity 
and mortality worldwide and is a major etiological factor in heart and 
vascular diseases. An important regulatory mechanism of blood pres-
sure (BP) is the renin angiotensin system (RAS). In fact, all the first-
line drugs for the treatment of hypertension act on some component 
of the RAS. However, these treatments frequently lead to the devel-
opment of changes in morphology and physiology characterized by 
vascular complications. It is therefore necessary to consider adjuvant 
therapies to improve the outcome of treatments and therefore in the 
quality of life of patients with HBP. A therapy that has been shown 
to improve the clinical condition of patients with HBP is hyperbaric 
oxygenation (HBO), in which the patient is subject to a pressure 
of 2 atmospheres absolute with an oxygen concentration of 100%. 
This therapy has been shown to improve vascular smooth muscle 
relaxation, although the mechanism of action has not yet been speci-
fied. The aim of this study is to examine the role of the RAS in the 
relaxation of vessels in hypertensive rats that is produced by HBO.
Patients (or Materials) and Methods: Male Wistar rats were used 
(340 ± 20 g) at standard conditions (light/dark cycle, water and food 
ad libitum), and hypertension was induced by a previously described 
surgical method (PAGE). Stable hypertension was established at 
7 days’ postsurgery (for plethysmographic method). On the eighth 
day, HBO therapy began, and was carried out 5 days per week for 
4 weeks. Rats were sacrificed at the end of treatment, obtaining 
thoracic and abdominal aorta. The endothelium was removed by a 
mechanical method, aortic rings were mounted, and concentration 
response curves were constructed according to increasing doses of 
ANG II for all groups with and without HBO. The results are ana-
lyzed with 2-way ANOVA and post hoc Von Ferroni.
Results: Diastolic pressure was found to be 150 (10) mm Hg, con-
sistent with the definition of hypertension. The angiotesin contractile 
response was lower in the groups of rats treated with HBO, compared 
with the 2 control groups (untreated and SHAM animals).
Conclusion: HBO therapy reduced vascular reactivity in both seg-
ments of the hypertensive rat aorta. This suggests that HBO could 
possibly be used with hypertensive patients to reduce the use of drugs 
in therapy.
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Introduction: Congestive heart failure (CHF), caused by ischemic 
cardiomyophaty and diabetes II-type, is a devastating clinical prob-
lem.The aim of this study was highlight several advances in the under-
standing of molecular pathways involved in cardiac hypertrophy, 
inflammatory signaling, and oxidant stress that may play a key role 
in altering transcriptional regulatory networks regulating adapta-
tion or maladaptation, and consequently, the transition to overt HF.
Patients (or Materials) and Methods: A total of 56 patients aged 
53 (6) years, with ischemic cardiomyophaties (ICMP) accompanied 
with the diabetes II-type were included in the study. Entry criteria’s 
were: the left ventricular ejection fraction (LVEF) < 40% and mild 
LV dilatation, symptoms of CHF for the last 2 months, at least. All 
patients including in the study were randomized into 2 groups; con-
trol received standard therapy (digoxin 0.025 mg per day, inhibitor 
of ACE and a diuretic, n = 29) and the main one (n = 30) an inhibitor 
of ACE, a diuretic, and Adenocin (2 ampoules diluted in 50-100 mL 
of saline in infused IV). There were no significant differences in base-
line characteristics (demographic and anamnesis) between groups. 
Plasma levels of cytokines (interleukine-1β [L-1β ], tumor necrosis 
factor [TNF-a]), redox-potential NAD/NADH, superoxide anion 
production, activities of superoxide dismutase (SOD), and catalase 
(CT) were determined.
Results: It has been shown that in the control group, the functional 
class (FC) of CHF by NYHA decreased by 12%, the dyspnea by 
49%, lung congestion by 78%, hepatomegaly by 70%, and periph-
eral edema improved by 45%. The total CHF score improved by 
52%. In the main group, the FC of CHF improved by 25%, dyspnea 
and lung congestion disappeared completely, hepatomegaly improved 
by 74%, peripheral edema -by 88%. The total score improved by 
67%. In the group receiving Adenocin, LVEF improved by 16% 
(from 26% to 42%), stroke volume improved by 28%. Hence, the 
optimal treatment of CHF would be achieved through increase in the 
energy supply: redox-potential NAD/NADH increased by 34%, the 
content of pyridine nucleotide in the plasma by 40%. The activity of 
the marker of hyperactivation of the system of reactive oxygen pro-
duction decreased by 48% and activities of SOD and CT increased 
by 45% and 60%, respectively. Treatment with Adenocin leads to a 
markedly improve of the state of immune system and as a result the 
content of proinflammatory cytokines, IL-1 β and TNF-a decreased 
by 49 and 38%, respectively.
Conclusion: The modern approach to treatment of HF is multidis-
ciplinary, given that mandatory multiorgan attention is required to 
ensure early good outcome in these high-risk patients with ICMP 
and diabetes II-type. From the present results, it is evident that 
Adenocin cessates cardiac remodeling during the development of 
cardiac hypertrophy and resrores functional activity of the myo-
cardium.
Disclosure of Interest: None declared.
Poster Presentation Abstracts
2013 e47
PP098—NiCoraNdil iNduCed eNdoThelium-
iNdePeNdeNT relaxaTioN of arTerial 
byPaSS grafT
M. Marinko1*; A. Novakovic1; I. Stojanovic2,3; P. Milojevic2,3;  
M. Jovic2,3; D. Nenezic2,3; N. Ugresic1; V. Kanjuh4; Q. Yang5,6; and 
G.-W. He5,6,7
1Department of Pharmacology, Faculty of Pharmacy, University of 
Belgrade; 2Faculty of Medicine, University of Belgrade; 3Institute 
for Cardiovascular Diseases “Dedinje”; 4Academy of Sciences and 
Arts, Belgrade, Serbia; 5Department of Surgery, Chinese University 
of Hong Kong, Hong Kong, Hong Kong; 6TEDA International 
Cardiovascular Hospital, Medical College, Nankai University, 
Tianjin, China; and 7Providence Heart & Vascular Institute, 
Albert Starr Academic Center, Department of Surgery, Oregon 
Health and Science University, Portland, Oregon
Introduction: Spasm of the human internal mammary artery (HIMA) 
is a rare but life-threatening complication after coronary artery 
bypass grafting (CABG). The reversal of this vasospasm is often chal-
lenging, and the most effective therapy is not well defined. The pre-
sent study was aimed to investigate vasorelaxant effect of nicorandil, 
K+ channel opener, on the HIMA and to define the role of different 
K+ channel subtypes in nicorandil action on this blood vessel.
Patients (or Materials) and Methods: Discarded segments of HIMA 
were collected from patients undergoing CABG and studied in organ 
baths. HIMA rings were precontracted with phenylephrine (10 µM) 
followed by cumulatively adding increasing doses of nicorandil. The 
endothelium was removed mechanically.
Results: Nicorandil (0.001 µM–300 µM) induced a concentration-
dependent relaxation of HIMA rings precontracted by phenylephrine. 
Glibenclamide (10 μ M), a highly selective blocker of ATP-sensitive 
K+ (KATP) channels, partially inhibited relaxation of HIMA induced 
by nicorandil. Tetraethylammonium (TEA, 1 mM), a nonselective 
blocker of Ca2+-activated K+ (KCa) channels, as well as iberiotoxin 
(100 nM), a most selective blocker of large-conductance KCa (BKCa) 
channels, partly antagonized relaxation of HIMA. A nonselective 
blocker of voltage-gated K+ (KV) channels, 4-aminopyridine (4-AP, 
0.5 mM), as well as margatoxin (10 nM), a potent inhibitor of KV1.3 
channels, did not significantly modify the nicorandil-induced relaxa-
tion of HIMA.
Conclusion: The results from our study demonstrate that, in HIMA, 
nicorandil has a potent vasorelaxant effect which is endothelium-
independent. It seems that mechanism of this relaxation includes 
KATP and 4-AP-sensitive K+ channels located in the smooth muscle 
of HIMA.
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Introduction: Thrombosis is 1 of the major causes of death world-
wide. Atherothrombotic diseases such as myocardial or cerebral 
infarction are serious consequences of the thrombus formed in 
blood vessels. Nattokinase is new fibrinolytic enzyme with a 
molecular weight of 27 728 Da that cleaves directly cross-linked 
fibrin in vitro. In this study, we investigated the effect of nat-
tokinase supplementation on thrombus formation using different 
animal models.
Patients (or Materials) and Methods: To study the fibrinolytic activ-
ity, in vitro clot dissolution assay was done in which clot was formed 
in helix and then kept in contact with different concentrations of 
nattokinase and streptokinase (standard drug) and its clot dissolution 
property was studied. Further it was studied for its antithrombotic 
activity in venous thrombosis. Rats were pretreated orally for 7 days 
with Nattokinase (100 and 200 mg/kg). One hour after the last dose, 
stasis was developed in the inferior vena cava in rats, and its activity 
was intensified with the help of ferric chloride. It was also studied 
for its antithrombotic activity in arterial thrombosis using arterio-
venous shunt-induced thrombosis in rats. In this rats were pretreated 
orally for 7 days with Nattokinase (100 and 200 mg/kg) and on last 
day 1 hour after last dose thrombosis was induced by arterio-venous 
shunt. In both the above studies, % inhibition of thrombus forma-
tion was calculated. Because hemorrhage is an important side effect 
of antithrombotic and thrombolytic therapies, the drug was studied 
for its effect on hemorrhage using rat tail transaction method. Here, 
effect of 7 days pretreatment of 2 doses of nattokinase (100 and 200 
mg/kg) on hemorrhage was studied.
Results: In in vitro clot dissolution assay, there was significant and 
dose-dependent clot dissolution with different concentration of nat-
tokinase. Maximum activity, 94.43 % inhibition, was seen in 3000ug/
mL concentration which was comparable with 1000 IU of strepto-
kinase. In venous thrombosis model, it showed significant and dose-
dependent inhibition of thrombus formation as indicated by decrease 
in weight of thrombus. Antithrombotic potential of nattokinase at the 
highest dose (200 mg/kg) showed 45.431% inhibition with respect to 
saline control group. In arterio-venous shunt ,it showed no significant 
inhibition of thrombus formation on thrombogenic surface. In the 
rat tail transaction model, both the doses of nattokinase (100 and 
200 mg/kg) has significantly increased the bleeding time with not 
much effect on blood loss. Also, the platelet MDA was significantly 
decreased in both groups treated with 100 and 200 mg/kg of nat-
tokinase.
Conclusion: The results of various in vitro and in vivo models stud-
ied indicate that nattokinase has a good potential as an antithrom-
botic and fibrinolytic agent.
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Introduction: High blood pressure (HBP) is a disease with high 
morbidity and mortality worldwide and is considered 1 of the main 
etiologic factors of multiple cardiac pathologies like cardiac hyper-
trophy, myocardial infarction, among others. One of the regulatory 
mechanisms of blood pressure is the renin angiotensin system (RAS), 
so much so that the first-line drugs in the treatment of hyperten-
sion are directed to some of the components of the RAS. However, 
these treatments frequently lead to the development of changes in 
morphology and physiology characterized by vascular complications 
.It is therefore necessary to consider adjuvant therapies to improve 
the outlook and quality of life of patients with HBP. A therapy that 
has been shown clinically to improve the condition of patients with 
HBP is hyperbaric oxygenation (HBO), which consists in subject-
ing a subject at a pressure > 2 atmospheres absolute with an 100% 
oxygen. This therapy has been shown to improve vascular smooth 
muscle relaxation, although the mechanism of action has not yet 
been specified.
